sr141716 has been researched along with Liver Dysfunction in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chorvat, RJ | 1 |
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T | 1 |
Avraham, Y; Berry, EM; Gabbay, E; Ilan, Y; Israeli, E | 1 |
Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J | 1 |
2 review(s) available for sr141716 and Liver Dysfunction
Article | Year |
---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
Endocannabinoids and liver disease--review.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Endocannabinoids; Glycerides; Humans; Liver Diseases; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
1 trial(s) available for sr141716 and Liver Dysfunction
Article | Year |
---|---|
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss | 2017 |
1 other study(ies) available for sr141716 and Liver Dysfunction
Article | Year |
---|---|
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |